First‐line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations

Osimertinib is the standard treatment for non‐small cell lung cancer (NSCLC) with an active epidermal growth factor receptor (EGFR) mutation and a T790M mutation—present in cases of acquired resistance. However, there have been no reports on the efficacy of osimertinib in patients with EGFR G719S an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Noriaki, Masuda, Takeshi, Ooka, Ikuko, Hosoya, Takatsune, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Horimasu, Yasushi, Nakashima, Taku, Miyamoto, Shintaro, Iwamoto, Hiroshi, Fujitaka, Kazunori, Hamada, Hironobu, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888148/
https://www.ncbi.nlm.nih.gov/pubmed/35076999
http://dx.doi.org/10.1111/1759-7714.14288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888148/
https://www.ncbi.nlm.nih.gov/pubmed/35076999
http://dx.doi.org/10.1111/1759-7714.14288

Ejemplares similares